DrugPatentWatch Database Preview
Sodium zirconium cyclosilicate - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for sodium zirconium cyclosilicate and what is the scope of freedom to operate?
Sodium zirconium cyclosilicate
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sodium zirconium cyclosilicate has one hundred and five patent family members in twenty-nine countries.
There are one thousand four hundred and seventy-two drug master file entries for sodium zirconium cyclosilicate. One supplier is listed for this compound.
Summary for sodium zirconium cyclosilicate
| International Patents: | 105 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 1472 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 11 |
| Patent Applications: | 1 |
| DailyMed Link: | sodium zirconium cyclosilicate at DailyMed |
Recent Clinical Trials for sodium zirconium cyclosilicate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AstraZeneca | Phase 4 |
| Zealand University Hospital | Phase 4 |
| Steno Diabetes Center Copenhagen | Phase 4 |
Synonyms for sodium zirconium cyclosilicate
| 17141-74-1 |
| CBTCHTJSGLCFMY-UHFFFAOYSA-N |
| Sodium zirconium silicate (Na2ZrSi3O9) |
| UZSi 9 |
| UZSi-9 |
| ZS 9 |
| ZS-9 compound |
US Patents and Regulatory Information for sodium zirconium cyclosilicate
Expired US Patents for sodium zirconium cyclosilicate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astrazeneca Pharms | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-001 | May 18, 2018 | Start Trial | Start Trial |
| Astrazeneca Pharms | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-002 | May 18, 2018 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for sodium zirconium cyclosilicate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3065710 | Start Trial |
| China | 106170283 | Start Trial |
| Argentina | 095600 | Start Trial |
| Mexico | 2018004440 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015070019 | Start Trial |
| Philippines | 12018500786 | Start Trial |
| European Patent Office | 2673237 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for sodium zirconium cyclosilicate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0806968 | SPC/GB07/011 | United Kingdom | Start Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| 1499331 | 13C0055 | France | Start Trial | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220 |
| 0480717 | SPC/GB98/025 | United Kingdom | Start Trial | PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115 |
| 1758590 | LUC00029 | Luxembourg | Start Trial | PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401 |
| 2203431 | 15C0013 | France | Start Trial | PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119 |
| 1666481 | 17C1031 | France | Start Trial | PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
| 1259550 | 08C0052 | France | Start Trial | PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
